A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below,
- to collect the safety information of JR-141
- to evaluate the plasma pharmacokinetics of JR-141
- to explore the efficacy of JR-141 on MPS II-related central nervous system symptoms and
general symptoms